Impact of Bevacizumab on Experimentally Induced Endometriotic Lesions: Angiogenesis, Invasion, Apoptosis, and Cell Proliferation

Ana Carolina Tagliatti Zani, Fernando Passador Valério, Fernando Passador Valerio, Juliana Meola, Alfredo Ribeiro da Silva, Antônio Alberto Nogueira, Antonio Alberto Nogueira, Francisco José Candido-Dos-Reis, Francisco José Cândido dos Reis, Omero Benedicto Poli-Neto, Omero Benedicto Poli‐Neto, Julio Cesar Rosa-E-Silva, Júlio César Rosa e Silva
Reproductive sciences (Thousand Oaks, Calif.) · 2020 · vol. 27(10) , pp. 1943–1950 · doi:10.1007/s43032-020-00213-7 · PMID:32542537 · W3034230158
article OA: closed CC0 ⤵ 9 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed

My notes (saved in your browser only)

Condition tags

mesh:D004715

MeSH descriptors

Apoptosis Bevacizumab Cell Proliferation Endometriosis Neovascularization, Pathologic Animals Apoptosis Bevacizumab Bevacizumab Cell Proliferation Disease Models, Animal Endometriosis Endometriosis Endometrium Endometrium Endometrium Female Matrix Metalloproteinase 9 Matrix Metalloproteinase 9 Neovascularization, Pathologic

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (38)

Cited by (9)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:21:59.141895+00:00
License: CC0 · commercial use OK